Stay updated on Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Sign up to get notified when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.

Latest updates to the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 has been added, and the funding-lapse notice has been removed. This update does not modify study content, eligibility criteria, or outcomes.SummaryDifference0.4%

- Check21 days agoChange DetectedThe page now shows a government funding notice regarding potential delays and open status of the NIH Clinical Center, and the site revision was updated from v3.4.0 to v3.4.1.SummaryDifference0.4%

- Check28 days agoChange DetectedMinor UI/metadata updates were made: the glossary option is now shown, revision labels were updated to Revision: v3.4.0 with capitalization tweaks for No FEAR Act data, and older labels such as 'Last Update Submitted that met QC Criteria' were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays Revision: v3.3.4, replacing v3.3.3. This is a minor metadata update and does not affect study data, eligibility criteria, or locations.SummaryDifference0.1%

- Check63 days agoChange DetectedFooter now displays Revision: v3.3.3; the previously listed Revision: v3.3.2 and the HHS Vulnerability Disclosure link were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check92 days agoChange DetectedMinor site release note: Revision: v3.3.2 replaces v3.2.0, with no changes to study content or visible page data. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Temelimab for Neuropsychiatric Symptoms in Post-COVID: Clinical Trial page.